1 of 1
Story summary
- The FDA opened a public comment period on a proposed AI-driven pilot aimed at improving safety monitoring and patient recruitment in clinical trials.
- The FDA will start real-time data reviews of AstraZeneca’s Phase 2 lymphoma trial, testing a combination therapy at MD Anderson and the University of Pennsylvania, and Amgen’s Phase 1b lung-cancer study, which uses a Paradigm Health platform.
- Amgen’s study targets small-cell lung carcinoma.
